1026631-02-6

Basic information

• Product Name: 2-(2,6-Dimethyl-phenyl)-acetimidic acid ethyl ester
• Synonyms: 2-(2,6-Dimethyl-phenyl)-acetimidic acid ethyl ester
• CAS NO: 1026631-02-6
• Molecular Weight: 191.273
• Mol File: 1026631-02-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(2,6-Dimethyl-phenyl)-acetimidic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,6-Dimethyl-phenyl)-acetimidic acid ethyl ester(1026631-02-6)
• EPA Substance Registry System: 2-(2,6-Dimethyl-phenyl)-acetimidic acid ethyl ester(1026631-02-6)

Safety Data

• Hazardous Substances Data: 1026631-02-6(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 54708-14-4 2,6-dimethylphenylacetonitrile 
• 83902-02-7 2,6-dimethylbenzyl bromide 

Relevant articles and documents

Benzylimidazolines as h5-HT(1B/1D) serotonin receptor ligands: A structure-affinity investigation

Benzylimidazolines may represent a class of 5-HT(1D) ligands that has yet to be exploited. On the basis of a previous report that the 2- (substituted-benzyl)imidazoline α-adrenergic agonist oxymetazoline (8) binds with high affinity at calf brain 5-HT(1D) receptors, we explored the structure-affinity relationships of a series of related derivatives. Each of the aromatic substituents was removed and then reinstated in a systematic manner to determine the influence of the individual substituents on binding. It was found that all of the aromatic substituents of 8 act in concert to impart high affinity. However, although the 3-hydroxy group could be removed without significantly reducing affinity for h5-HT(1D) (i.e., human 5- HT(1Dα)) receptors, this modification reduced h5-HT(1B) (i.e., human 5- HT(1Dβ)) receptor affinity by nearly 50-fold. The 2,6-dimethyl groups also contribute to binding but seem to play a greater role for h5-HT(1B) binding than h5-HT(1D) binding. With the appropriate structural modifications, several compounds were identified that display 20- to > 100-fold selectivity for h5-HT(1D) versus h5-HT(1B) receptors. Preliminary functional data suggest that these compounds behave as agonists. Given that 5-HT(1D) agonists are currently being explored for their antimigraine action and that activation of h5-HT(1B) receptors might be associated with cardiovascular side effects, h5- HT(1D)selective agents may offer a new lead for the development of therapeutically efficacious agents.